A. Gilles, B. Pharmacie-clinique-alain, B. Jean-claude, C. Santé-publique-christine, F. Pharmacologie-cardiovasculaire-chantal et al., Chimie physique générale Pharmacie galénique Chimie thérapeutique

B. Sandrine, B. Mariette, B. Biologie-cellulaire-emmanuelle, . Communication, B. Santé-isabelle et al., Chimie thérapeutique Chimie thérapeutique

B. Ariane, B. Cédric, C. Igor, C. Chimie-analytique-joël, D. Sébastien et al., Hématologie -Génie Biologique, Chimie thérapeutique François DUPUIS.............................................. Pharmacologie Raphaël DUVAL .............................................. Microbiologie clinique

F. Adil, Biophysique-acoustique

F. Luc, G. Caroline, .. Di-stasio, G. Expertise-biopharmacologique-stéphane, H. Pharmacie-clinique-thierry et al., Biophysique

S. Anne, S. Pharmacie-galénique-marie-paule, B. Mycologie, T. Nathalie, T. Santé-publique-gabriel et al., Pharmacie galénique ASSISTANTS HOSPITALO-UNIVERSITAIRES, Biochimie et Biologie

E. Van-cutsem, M. Peeters, S. Siena, Y. Humblet, A. Hendlisz et al., Open-Label Phase III Trial of Panitumumab Plus Best Supportive Care Compared With Best Supportive Care Alone in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer, Journal of Clinical Oncology, vol.25, issue.13, pp.1658-64, 2007.
DOI : 10.1200/JCO.2006.08.1620

C. Pelloski, K. Ballman, A. Furth, L. Zhang, E. Lin et al., Epidermal Growth Factor Receptor Variant III Status Defines Clinically Distinct Subtypes of Glioblastoma, Journal of Clinical Oncology, vol.25, issue.16, pp.2288-94, 2007.
DOI : 10.1200/JCO.2006.08.0705

T. Byers, Two Decades of Declining Cancer Mortality: Progress with Disparity, Annual Review of Public Health, vol.31, issue.1, pp.121-153, 2010.
DOI : 10.1146/annurev.publhealth.121208.131047

C. Sawyers, The cancer biomarker problem, Nature, vol.353, issue.7187, pp.548-52, 2008.
DOI : 10.1038/nm1107-1276b

N. Papadopoulos, K. Kinzler, and B. Vogelstein, The role of companion diagnostics in the development and use of mutation-targeted cancer therapies, Nature Biotechnology, vol.5, issue.8, 2006.
DOI : 10.1038/nrc1609

R. Perez-soler, A. Chachoua, L. Hammond, E. Rowinsky, M. Huberman et al., Determinants of Tumor Response and Survival With Erlotinib in Patients With Non???Small-Cell Lung Cancer, Journal of Clinical Oncology, vol.22, issue.16, pp.3238-3285, 2004.
DOI : 10.1200/JCO.2004.11.057

Z. Uhry, M. Colonna, L. Remontet, P. Grosclaude, N. Carre et al., Estimating infra-national and national thyroid cancer incidence in France from cancer registries data and national hospital discharge database, European Journal of Epidemiology, vol.53, issue.4, pp.607-621, 2007.
DOI : 10.1038/bjc.1993.61

URL : https://hal.archives-ouvertes.fr/inserm-00341262

P. Quirke, M. Risio, R. Lambert, L. Von-karsa, M. Vieth et al., Quality assurance in pathology in colorectal cancer screening and diagnosis-European recommendations. Virchows Arch Cancer incidence and mortality in France over the period 1980-2005. Rev Epidemiol Sante Publique HAS. Guide Affection Longue Durée -Cancer colorectal, pp.159-75, 2008.

G. Chang, M. Overman, C. Eng, D. Sargent, and D. Larson, Ann Oncol Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy, Molecular markers and biological targeted therapies in metastatic colorectal cancer: expert opinion and recommendations derived from the 11th ESMO/World Congress on Gastrointestinal Cancer, pp.3677-83, 2009.

V. Boige, D. Malka, J. Taieb, J. Pignon, and M. Ducreux, Colorectal cancer: prognostic molecular markers]):21-32. 15. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis, Gastroenterol Clin Biol. Cell, vol.28, issue.1, 1990.

M. Scartozzi, I. Bearzi, R. Berardi, A. Mandolesi, C. Pierantoni et al., Epidermal growth factor receptor (EGFR) downstream signalling pathway in primary colorectal tumours and related metastatic sites: optimising EGFR-targeted treatment options, British Journal of Cancer, vol.1, issue.1, 2007.
DOI : 10.1038/sj.bjc.6603847

E. Abdalla, R. Adam, A. Bilchik, D. Jaeck, J. Vauthey et al., Improving Resectability of Hepatic Colorectal Metastases: Expert Consensus Statement, Annals of Surgical Oncology, vol.12, issue.10, pp.1271-80, 2006.
DOI : 10.1007/BF02725339

J. Faivre, S. Manfredi, A. Bouvier, P. Grosclaude, G. Launoy et al., Are there regional differences in the management of colon cancer in France? Eur J Cancer Prev, Bull Acad Natl Med, vol.187, issue.5, pp.815-837, 2003.

. Feb, Référentiel Oncolor -http://www.oncolor.org. [cited; Available from, pp.31-38

P. Lévy, H. Sorbye, B. Glimelius, G. Poston, P. Schlag et al., Hépato-gastro-entérologie -Editions Masson, 2009.

S. Ricci, I. Brunetti, E. Pfanner, G. Allegrini, and C. Barbara, Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest, J Clin Oncol, vol.37125, issue.961713, pp.1007-161670, 2007.

G. Masi, S. Cupini, L. Marcucci, E. Cerri, F. Loupakis et al., Treatment with 5-Fluorouracil/Folinic Acid, Oxaliplatin, and Irinotecan Enables Surgical Resection of Metastases in Patients With Initially Unresectable Metastatic Colorectal Cancer, Annals of Surgical Oncology, vol.4, issue.1, 2006.
DOI : 10.1001/archsurg.1976.01360220026004

M. Ychou, F. Viret, A. Kramar, F. Desseigne, E. Mitry et al., Tritherapy with fluorouracil/leucovorin, irinotecan and oxaliplatin (FOLFIRINOX): a phase II study in colorectal cancer patients with non-resectable liver metastases Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: updated results from the BICC-C study, Cancer Chemother Pharmacol. J Clin Oncol Feb, vol.6226, issue.14, pp.195-201689, 2008.

M. Fluorouracil-koopman, N. Antonini, J. Douma, J. Wals, A. Honkoop et al., without cetuximab in the first-line treatment of metastatic colorectal cancer Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial, J Clin Oncol Feb Lancet, vol.1027, issue.31, pp.663-71, 2007.

M. Seymour, T. Maughan, J. Ledermann, C. Topham, R. James et al., Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial, The Lancet, vol.370, issue.9582, pp.143-52, 2007.
DOI : 10.1016/S0140-6736(07)61087-3

F. Bidard, C. Tournigand, T. Andre, M. Mabro, A. Figer et al., Efficacy of FOLFIRI-3 (irinotecan D1,D3 combined with LV5-FU) or other irinotecan-based regimens in oxaliplatin-pretreated metastatic colorectal cancer in the GERCOR OPTIMOX1 study, Annals of Oncology, vol.24, issue.3, pp.1042-1049, 2009.
DOI : 10.1200/JCO.2005.03.0106

D. Hanahan and R. Weinberg, The hallmarks of cancer. Cell, Jan, vol.7100, issue.1, pp.57-70, 2000.

P. Blume-jensen and T. Hunter, Oncogenic kinase signalling, Nature. May, vol.17411, issue.6835, pp.355-65, 2001.

W. Ma, A. Adjei, and J. Soria, Novel agents on the horizon for cancer therapy. CA Cancer J Clin, Thérapies moléculaires ciblées -De la biologie aux applications, pp.111-148, 2008.

K. Imai, A. Takaoka, E. Van-cutsem, P. Rougier, C. Kohne et al., Comparing antibody and small-molecule therapies for cancer, Nature Reviews Cancer, vol.23, issue.Suppl. 2, pp.714-741, 2006.
DOI : 10.1038/nbt1068

N. Ferrara, H. Gerber, J. Lecouter, S. Koch, L. Gualandi et al., The biology of VEGF and its receptors Vascular endothelial growth factors and receptors: anti-angiogenic therapy in the treatment of cancer, Nat Med. Mol Aspects Med, vol.235932, issue.862, pp.907-927, 2003.

R. Leite-de-oliveira, A. Hamm, and M. Mazzone, Growing tumor vessels: More than one way to skin a cat ??? Implications for angiogenesis targeted cancer therapies, Molecular Aspects of Medicine, vol.32, issue.2
DOI : 10.1016/j.mam.2011.04.001

F. Kabbinavar, H. Hurwitz, J. Yi, S. Sarkar, and O. R. Rosen, Addition of Bevacizumab to Fluorouracil-Based First-Line Treatment of Metastatic Colorectal Cancer: Pooled Analysis of Cohorts of Older Patients From Two Randomized Clinical Trials, Journal of Clinical Oncology, vol.27, issue.2, pp.71-87, 2009.
DOI : 10.1200/JCO.2008.17.7931

T. Price, J. Hardingham, C. Lee, A. Weickhardt, A. Townsend et al., Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study Impact of KRAS and BRAF Gene Mutation Status on Outcomes From the Phase III AGITG MAX Trial of Capecitabine Alone or in Combination With Bevacizumab and Mitomycin in Advanced Colorectal Cancer, J Clin Oncol J Clin Oncol, vol.2629, issue.12, pp.2013-2022, 2008.

R. Jain, D. Duda, J. Clark, and J. Loeffler, Lessons from phase III clinical trials on anti-VEGF therapy for cancer, Nature Clinical Practice Oncology, vol.25, issue.1, pp.24-40, 2006.
DOI : 10.1016/j.urolonc.2004.01.011

C. Kohne, How to integrate molecular targeted agents in the continuum of care, Annals of Oncology, vol.370, issue.9582, pp.134-143, 2010.
DOI : 10.1016/S0140-6736(07)61087-3

C. Allegra, G. Yothers, O. Connell, M. Sharif, S. Petrelli et al., Phase III Trial Assessing Bevacizumab in Stages II and III Carcinoma of the Colon: Results of NSABP Protocol C-08, Ellis LM, Hicklin DJ. VEGF-targeted therapy: mechanisms of anti-tumour activity, pp.11-17, 2011.
DOI : 10.1200/JCO.2010.30.0855

J. Feige, Tumor angiogenesis: recent progress and remaining challenges]. Bull Cancer, pp.1305-1315, 2010.

H. Dvorak, Vascular Permeability Factor/Vascular Endothelial Growth Factor: A Critical Cytokine in Tumor Angiogenesis and a Potential Target for Diagnosis and Therapy, Journal of Clinical Oncology, vol.20, issue.21, pp.4368-80, 2002.
DOI : 10.1200/JCO.2002.10.088

M. Thomas, D. Malka, V. Boige, N. Jacques, N. Vimond et al., Toward improved outcomes in hepatocellular carcinoma: overcoming the challenges of an "orphan" tumor. Gastrointest Cancer Res Clinical value of circulating endothelial cell levels in metastatic colorectal cancer patients treated with firstline chemotherapy and bevacizumab High levels of vascular endothelial growth factor and its receptors (VEGFR-1, VEGFR-2, neuropilin-1) are associated with worse outcome in breast cancer, Ann Oncol Hum Pathol, vol.3, issue.2, pp.73-56, 2008.

Y. Chang, M. Chang, S. Wei, Y. Tien, C. Hsu et al., Serum Vascular Endothelial Growth Factor/Soluble Vascular Endothelial Growth Factor Receptor 1 Ratio Is an Independent Prognostic Marker in Pancreatic Cancer, Pancreas, vol.37, issue.2, pp.1835-43145, 2008.
DOI : 10.1097/MPA.0b013e318164548a

F. Bibeau, L. Arnould, M. Bralet, P. Rochaix, and J. Sabourin, Biomarkers in tissue from patients with upper gastrointestinal cancers treated with erlotinib and bevacizumab [EGFR expression in colorectal cancer and role in tumorigenesis]. Bull Cancer, Cancer Biol Ther, vol.1192, issue.60, pp.732-741, 2005.

J. Baselga, Targeting the epidermal growth factor receptor: a clinical reality, J Clin Oncol Sep, vol.1519, pp.41-45, 2001.

E. Cidon, F. Bibeau, E. Lopez-crapez, D. Fiore, F. Thezenas et al., The challenge of metastatic colorectal cancer Impact of Fc{gamma}RIIa-Fc{gamma}RIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases downregulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors, Clin Med Insights Oncol. J Clin Oncol. Am J Pathol, vol.427, issue.64, pp.55-601122, 1997.

D. Wheeler, E. Dunn, and P. Harari, Understanding resistance to EGFR inhibitors???impact on future treatment strategies, Nature Reviews Clinical Oncology, vol.6, issue.9, pp.493-507, 2010.
DOI : 10.1091/mbc.4.1.121

J. Ouwerkerk and C. Boers-doets, Best practices in the management of toxicities related to anti-EGFR agents for metastatic colorectal cancer, European Journal of Oncology Nursing, vol.14, issue.4, pp.337-386, 2010.
DOI : 10.1016/j.ejon.2010.03.004

O. Bouche, E. Scaglia, Z. Reguiai, V. Singha, H. Brixi-benmansour et al., Targeted biotherapies in digestive oncology: management of adverse effects] Reduced incidence of infusion-related reactions in metastatic colorectal cancer during treatment with cetuximab plus irinotecan with combined corticosteroid and antihistamine premedication. Cancer Randomized double-blind trial of prophylactic oral minocycline and topical tazarotene for cetuximabassociated acne-like eruption, Gastroenterol Clin Biol. J Clin Oncol, vol.3311625, issue.72734, pp.306-221827, 2007.

Y. Cao, C. Liao, A. Tan, L. Liu, and F. Gao, Meta-Analysis of Incidence and Risk of Hypomagnesemia with Cetuximab for Advanced Cancer, Biomarkers and surrogate endpoints: preferred definitions and conceptual framework, pp.459-65, 2010.
DOI : 10.1159/000321011

C. Oldenhuis, S. Oosting, J. Gietema, E. De-vries, D. Sargent et al., Prognostic versus predictive value of biomarkers in oncology Clinical trial designs for predictive marker validation in cancer treatment trials, Clin Pharmacol Ther Eur J Cancer. J Clin Oncol, vol.694423, issue.779, pp.89-95, 2001.

M. Buyse, Statistical issues in identifying, validating, and using molecular markers in clinical trials. ESMO -Impakt Breast cancer conference, p.79, 2009.

P. Hubert, Growth factors of the EGF family and their receptors]. Bull Cancer, Singh AB, Harris RC. Autocrine, paracrine and juxtacrine signaling by EGFR ligands, pp.137-182, 2007.

T. Holbro and N. Hynes, : Directing Key Signaling Networks Throughout Life, Annual Review of Pharmacology and Toxicology, vol.44, issue.1, pp.1183-93195, 2004.
DOI : 10.1146/annurev.pharmtox.44.101802.121440

D. Azria and J. Spano, Thérapies ciblées en cancérologie: Libbey Eurotext; 2006. 83. Sergina NV, Moasser MM. The HER family and cancer: emerging molecular mechanisms and therapeutic targets Gschwind A, Fischer OM, Ullrich A. The discovery of receptor tyrosine kinases: targets for cancer therapy, Trends Mol Med. Nat Rev Cancer, vol.134, issue.845, pp.527-34361, 2004.

B. Gusterson, K. Hunter, R. Bianco, T. Gelardi, V. Damiano et al., Should we be surprised at the paucity of response to EGFR inhibitors? Lancet Oncol Mechanisms of resistance to EGFR inhibitors, Targeted Oncology, vol.102, issue.861, pp.522-731, 2007.

K. Spindler, D. Olsen, J. Nielsen, I. Brandslund, H. Poulsen et al., Epidermal growth factor receptor and epidermal growth factor receptor variant III gene expression in metastatic colorectal cancer Clin Colorectal Cancer, of the type III epidermal growth factor receptor mutation in colorectal cancer, pp.214-222, 2006.

F. Ozcan, P. Klein, M. Lemmon, I. Lax, and J. Schlessinger, Signal transduction by epidermal growth factor occurs through the subclass of high affinity receptors On the nature of low-and high-affinity EGF receptors on living cells, J Cell Biol Proc Natl Acad Sci, vol.109103, issue.9015, pp.2495-5075735, 1989.

T. Ringerike, E. Stang, L. Johannessen, D. Sandnes, F. Levy et al., Highaffinity binding of epidermal growth factor (EGF) to EGF receptor is disrupted by overexpression of mutant dynamin (K44A) High-and low-affinity epidermal growth factor receptor-ligand interactions activate distinct signaling pathways, ):e15945. 93. Sako Y, Minoghchi S, Yanagida T. Single-molecule imaging of EGFR signalling on the surface of living cells, pp.16639-42168, 1998.

G. Liccardi, J. Hartley, and D. Hochhauser, EGFR nuclear translocation modulates DNA repair following cisplatin and ionizing radiation treatment, Cancer Res Feb, vol.171, issue.3, pp.1103-1117, 2011.
DOI : 10.1158/0008-5472.can-10-2384

URL : http://cancerres.aacrjournals.org/content/canres/71/3/1103.full.pdf

H. Lo and M. Hung, Nuclear EGFR signalling network in cancers: linking EGFR pathway to cell cycle progression, nitric oxide pathway and patient survival, British Journal of Cancer, vol.258, issue.2, pp.16-20, 2007.
DOI : 10.1006/excr.2000.4905

H. Lo, Nuclear mode of the EGFR signaling network: biology, prognostic value, and therapeutic implications, Discov Med, vol.10, issue.50, pp.44-51, 2010.

H. Lo, W. Xia, Y. Wei, M. Ali-seyed, S. Huang et al., Novel prognostic value of nuclear epidermal growth factor receptor in breast cancer Increased epidermal growth factor receptor gene copy number is associated with poor prognosis in head and neck squamous cell carcinomas, Cancer Res. Current situation of Panitumumab, Matuzumab, Nimotuzumab and Zalutumumab. Acta Oncol. J Clin Oncol, vol.654724, issue.9925, pp.338-489, 2005.

O. Dassonville, J. Formento, M. Francoual, A. Ramaioli, J. Santini et al., Expression of epidermal growth factor receptor and survival in upper aerodigestive tract cancer., Journal of Clinical Oncology, vol.11, issue.10, pp.1873-1881, 1993.
DOI : 10.1200/JCO.1993.11.10.1873

R. Hitt, E. Ciruelos, M. Amador, A. Benito, J. Sanchez et al., Prognostic value of the epidermal growth factor receptor (EGRF) and p53 in advanced head and neck squamous cell carcinoma patients treated with induction chemotherapy, European Journal of Cancer, vol.41, issue.3, 2005.
DOI : 10.1016/j.ejca.2004.10.014

J. Brabender, K. Danenberg, R. Metzger, P. Schneider, J. Park et al., Epidermal growth factor receptor and HER2-neu mRNA expression in non-small cell lung cancer Is correlated with survival, Clin Cancer Res, vol.7, issue.7, pp.1850-1855, 2001.

B. Burtness, Her signaling in pancreatic cancer, Expert Opinion on Biological Therapy, vol.24, issue.6, 2007.
DOI : 10.1001/jama.297.3.267

J. Giltnane, L. Ryden, M. Cregger, P. Bendahl, K. Jirstrom et al., Quantitative Measurement of Epidermal Growth Factor Receptor Is a Negative Predictive Factor for Tamoxifen Response in Hormone Receptor???Positive Premenopausal Breast Cancer, Journal of Clinical Oncology, vol.25, issue.21, pp.3007-3021, 2007.
DOI : 10.1200/JCO.2006.08.9938

C. Rocha-lima, H. Soares, L. Raez, and R. Singal, EGFR targeting of solid tumors. Cancer Control, pp.295-304, 2007.

D. Cohen, B. Lane, J. T. Magi-galluzzi, C. Finke, J. Rini et al., The Prognostic Significance of Epidermal Growth Factor Receptor Expressionin Clear-Cell Renal Cell Carcinoma: A Call for Standardized Methods for Immunohistochemical Evaluation, Clinical Genitourinary Cancer, vol.5, issue.4, pp.264-70, 2007.
DOI : 10.3816/CGC.2007.n.002

J. Raizer and . Her1, HER1/EGFR tyrosine kinase inhibitors for the treatment of glioblastoma multiforme, Journal of Neuro-Oncology, vol.63, issue.Suppl 7, pp.77-86, 2005.
DOI : 10.1200/JCO.2004.99.242

J. Edwards, P. Traynor, A. Munro, C. Pirret, B. Dunne et al., The role of HER1- HER4 and EGFRvIII in hormone-refractory prostate cancer. Clin Cancer Res, pp.123-153, 2006.

S. Bellone, G. Frera, G. Landolfi, C. Romani, E. Bandiera et al., Overexpression of epidermal growth factor type-1 receptor (EGF-R1) in cervical cancer: Implications for Cetuximab-mediated therapy in recurrent/metastatic disease, Gynecologic Oncology, vol.106, issue.3, pp.513-533, 2007.
DOI : 10.1016/j.ygyno.2007.04.028

J. Schlessinger, Ligand-induced, receptor-mediated dimerization and activation of EGF receptor. Cell, pp.669-72, 2002.

W. Cai, G. Niu, and X. Chen, Multimodality imaging of the HER-kinase axis in cancer, European Journal of Nuclear Medicine and Molecular Imaging, vol.9, issue.Pt 11, pp.186-208, 2008.
DOI : 10.1259/bjr.75.suppl_9.750024

D. Amin, M. Campbell, and M. Moasser, The role of HER3, the unpretentious member of the HER family, in cancer biology and cancer therapeutics, Seminars in Cell & Developmental Biology, vol.21, issue.9, 2010.
DOI : 10.1016/j.semcdb.2010.08.007

T. Holbro, G. Civenni, and N. Hynes, The ErbB receptors and their role in cancer progression, Experimental Cell Research, vol.284, issue.1, pp.99-110, 2003.
DOI : 10.1016/S0014-4827(02)00099-X

H. Kataoka, EGFR ligands and their signaling scissors, ADAMs, as new molecular targets for anticancer treatments, Journal of Dermatological Science, vol.56, issue.3, pp.148-53, 2009.
DOI : 10.1016/j.jdermsci.2009.10.002

G. Galizia, E. Lieto, D. Vita, F. Orditura, M. Castellano et al., Cetuximab, a chimeric human mouse anti-epidermal growth factor receptor monoclonal antibody, in the treatment of human colorectal cancer. Oncogene, pp.3654-60, 2007.

T. Hunter, The age of crosstalk: phosphorylation, ubiquitination, and beyond. Mol Cell, pp.730-738, 2007.

J. Olsen, B. Blagoev, F. Gnad, B. Macek, C. Kumar et al., Global, In Vivo, and Site-Specific Phosphorylation Dynamics in Signaling Networks, Cell, vol.127, issue.3, pp.635-683, 2006.
DOI : 10.1016/j.cell.2006.09.026

J. Robert, Signalisation cellulaire et cancer, 2010.
DOI : 10.1007/978-2-8178-0028-8

B. Jiang and L. Liu, PI3K/PTEN signaling in tumorigenesis and angiogenesis, Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics, vol.1784, issue.1, pp.19-65, 2009.
DOI : 10.1016/j.bbapap.2007.09.008

J. Engelman, Targeting PI3K signalling in cancer: opportunities, challenges and limitations, Nature Reviews Cancer, vol.16, issue.8, pp.550-62, 2009.
DOI : 10.4161/cc.7.5.5485

A. Bellacosa, C. Kumar, D. Cristofano, A. Testa, and J. , Activation of AKT Kinases in Cancer: Implications for Therapeutic Targeting, Adv Cancer Res, vol.94, pp.29-86, 2005.
DOI : 10.1016/S0065-230X(05)94002-5

G. Pines, W. Kostler, and Y. Yarden, Oncogenic mutant forms of EGFR: Lessons in signal transduction and targets for cancer therapy, FEBS Letters, vol.2, issue.12, pp.2699-706, 2010.
DOI : 10.1371/journal.pmed.0020313

C. Vogel, M. Cobleigh, D. Tripathy, J. Gutheil, L. Harris et al., Efficacy and Safety of Trastuzumab as a Single Agent in First-Line Treatment of HER2-Overexpressing Metastatic Breast Cancer, Journal of Clinical Oncology, vol.20, issue.3, pp.719-745, 2002.
DOI : 10.1200/JCO.20.3.719

K. Chung, J. Shia, N. Kemeny, M. Shah, G. Schwartz et al., Cetuximab Shows Activity in Colorectal Cancer Patients With Tumors That Do Not Express the Epidermal Growth Factor Receptor by Immunohistochemistry, Journal of Clinical Oncology, vol.23, issue.9, pp.1803-1813, 2005.
DOI : 10.1200/JCO.2005.08.037

L. Saltz, N. Meropol, P. Loehrer, . Sr, M. Needle et al., Phase II Trial of Cetuximab in Patients With Refractory Colorectal Cancer That Expresses the Epidermal Growth Factor Receptor, Journal of Clinical Oncology, vol.22, issue.7, pp.1201-1209, 2004.
DOI : 10.1200/JCO.2004.10.182

M. Hebbar, A. Wacrenier, C. Desauw, O. Romano, S. Cattan et al., Lack of usefulness of epidermal growth factor receptor expression determination for cetuximab therapy in patients with colorectal cancer. Anticancer Drugs, pp.855-862, 2006.

J. Hecht, E. Mitchell, M. Neubauer, H. Burris, P. Swanson et al., Lack of correlation between epidermal growth factor receptor status and response to Panitumumab monotherapy in metastatic colorectal cancer. Clin Cancer Res, pp.2205-2218, 2010.

J. Garcia-saenz, J. Sastre, D. Garcia, and E. , Biomarkers and anti-EGFR therapies for KRAS wild-type metastatic colorectal cancer, Clinical and Translational Oncology, vol.26, issue.11, pp.737-784, 2009.
DOI : 10.1016/j.bbapap.2007.09.008

A. Lievre, J. Bachet, V. Boige, A. Cayre, L. Corre et al., Mutations As an Independent Prognostic Factor in Patients With Advanced Colorectal Cancer Treated With Cetuximab, Journal of Clinical Oncology, vol.26, issue.3, pp.374-383, 2008.
DOI : 10.1200/JCO.2007.12.5906

URL : https://hal.archives-ouvertes.fr/hal-00363737

M. Krause and M. Baumann, Clinical biomarkers of kinase activity: examples from EGFR inhibition trials, Cancer and Metastasis Reviews, vol.23, issue.supplement, pp.387-402, 2008.
DOI : 10.1016/j.ijrobp.2006.10.038

P. Laurent-puig, A. Cayre, G. Manceau, E. Buc, J. Bachet et al., Metastatic Colon Cancer, Journal of Clinical Oncology, vol.27, issue.35, pp.5924-5954, 2009.
DOI : 10.1200/JCO.2008.21.6796

URL : https://hal.archives-ouvertes.fr/hal-00618089

S. Richman, G. Hutchins, M. Seymour, and P. Quirke, What can the molecular pathologist offer for optimal decision making? Ann Oncol, pp.123-132, 2010.

B. Voldborg, L. Damstrup, M. Spang-thomsen, and H. Poulsen, Epidermal growth factor receptor (EGFR) and EGFR mutations, function and possible role in clinical trials, Annals of Oncology, vol.8, issue.12, pp.1197-206, 1997.
DOI : 10.1023/A:1008209720526

A. Chopra, 2-amino-3-(4-isothiocyanatophenyl)propyl]-trans- (S,S)-cyclohexane-1,2 -diamine-pentaacetic acid (CHX-A''-DTPA) conjugated monoclonal antibody L8A4 against epidermal growth factor receptor variant III (EGFRvIII), 2010.

D. Fiore, F. Sesboue, R. Michel, P. Sabourin, J. Frebourg et al., Molecular determinants of anti-EGFR sensitivity and resistance in metastatic colorectal cancer, British Journal of Cancer, vol.25, issue.12, pp.1765-72, 2010.
DOI : 10.4161/cc.6.9.4211

C. Pratilas and D. Solit, Targeting the mitogen-activated protein kinase pathway: physiological feedback and drug response. Clin Cancer Res, pp.3329-3363, 2010.

G. Buhrman, G. Wink, and C. Mattos, Transformation Efficiency of RasQ61 Mutants Linked to Structural Features of the Switch Regions in the Presence of Raf, Structure, vol.15, issue.12, 2007.
DOI : 10.1016/j.str.2007.10.011

A. Lievre, H. Blons, and P. Laurent-puig, Oncogenic mutations as predictive factors in colorectal cancer, Oncogene, vol.15, issue.21, pp.3033-3076, 2010.
DOI : 10.1016/S0002-9440(10)65579-4

T. Pretlow, T. Brasitus, N. Fulton, C. Cheyer, and E. Kaplan, K-ras Mutations in Putative Preneoplastic Lesions in Human Colon, JNCI Journal of the National Cancer Institute, vol.85, issue.24, pp.2004-2011, 1993.
DOI : 10.1093/jnci/85.24.2004

A. Lievre, J. Bachet, L. Corre, D. Boige, V. Landi et al., KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer, Cancer Res, 2006.

R. Amado, M. Wolf, M. Peeters, E. Van-cutsem, S. Siena et al., Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer, Journal of Clinical Oncology, vol.26, issue.10, pp.1626-1660, 2008.
DOI : 10.1200/JCO.2007.14.7116

S. Benvenuti, A. Sartore-bianchi, D. Nicolantonio, F. Zanon, C. Moroni et al., Oncogenic Activation of the RAS/RAF Signaling Pathway Impairs the Response of Metastatic Colorectal Cancers to Anti-Epidermal Growth Factor Receptor Antibody Therapies, Cancer Research, vol.67, issue.6, pp.2643-2651, 2007.
DOI : 10.1158/0008-5472.CAN-06-4158

W. De-roock, H. Piessevaux, D. Schutter, J. Janssens, M. et al., KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab, Annals of Oncology, vol.90, issue.3, pp.508-523, 2008.
DOI : 10.1093/jnci/90.9.675

D. Fiore, F. Blanchard, F. Charbonnier, F. , L. Pessot et al., Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy, British Journal of Cancer, vol.14, issue.8, pp.1166-1175, 2007.
DOI : 10.1093/jnci/92.3.205

M. Frattini, P. Saletti, E. Romagnani, V. Martin, F. Molinari et al., PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients, British Journal of Cancer, vol.24, issue.8, pp.1139-1184, 2007.
DOI : 10.1016/j.ctrv.2003.10.003

S. Khambata-ford, C. Garrett, N. Meropol, M. Basik, C. Harbison et al., Mutation Status Predict Disease Control in Metastatic Colorectal Cancer Patients Treated With Cetuximab, Journal of Clinical Oncology, vol.25, issue.22, pp.3230-3237, 2007.
DOI : 10.1200/JCO.2006.10.5437

E. Van-custem, A meta-analysis of the CRYSTAL and OPUS studies combining cetuximab with chemotherapy (CT) as 1stline treatment for patients (pts) with metastatic colorectal cancer (mCRC): results according to KRAS and BRAF mutation status, Eur J Cancer, vol.7, p.345, 2009.

C. Bokemeyer, I. Bondarenko, J. Hartmann, D. Braud, F. Schuch et al., Cetuximab plus 5-FU/FA/oxaliplatin (FOLFOX-4) versus FOLFOX-4 in the first-line treatment of metastatic colorectal cancer (mCRC): OPUS, a randomised phase II study, J Clin Oncol, vol.25172, 2007.

H. Linardou, I. Dahabreh, D. Kanaloupiti, F. Siannis, D. Bafaloukos et al., Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer, The Lancet Oncology, vol.9, issue.10, pp.962-72, 2008.
DOI : 10.1016/S1470-2045(08)70206-7

S. Edkins, O. Meara, S. Parker, A. Stevens, C. Reis et al., Recurrent KRAS codon 146 mutations in human colorectal cancer, Cancer Biology & Therapy, vol.5, issue.8, pp.928-960, 2006.
DOI : 10.4161/cbt.5.8.3251

W. De-roock, B. Claes, D. Bernasconi, D. Schutter, J. Biesmans et al., Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis, The Lancet Oncology, vol.11, issue.8, pp.753-62, 2010.
DOI : 10.1016/S1470-2045(10)70130-3

F. Loupakis, A. Ruzzo, C. Cremolini, B. Vincenzi, L. Salvatore et al., KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer, British Journal of Cancer, vol.8, issue.4, pp.715-736, 2009.
DOI : 10.1038/onc.2008.335

M. Raman, W. Chen, and M. Cobb, Differential regulation and properties of MAPKs, Oncogene, vol.24, issue.22
DOI : 10.1016/j.str.2006.04.006

A. Sartore-bianchi, K. Bencardino, D. Nicolantonio, F. Pozzi, F. Funaioli et al., Integrated molecular dissection of the epidermal growth factor receptor (EFGR) oncogenic pathway to predict response to EGFR-targeted monoclonal antibodies in metastatic colorectal cancer, Targeted Oncology, vol.27, issue.30, pp.19-28, 2010.
DOI : 10.1007/s11523-010-0138-5

C. Mao, R. Liao, L. Qiu, X. Wang, H. Ding et al., BRAF V600E mutation and resistance to anti-EGFR monoclonal antibodies in patients with metastatic colorectal cancer: a meta-analysis, Molecular Biology Reports, vol.2, issue.4, pp.2219-2242, 2011.
DOI : 10.1038/35052073

A. Russo, S. Rizzo, G. Bronte, N. Silvestris, G. Colucci et al., The Long and Winding Road to Useful Predictive Factors for Anti-EGFR Therapy in Metastatic Colorectal Carcinoma: The KRAS/BRAF Pathway, Oncology, vol.77, issue.1, pp.57-68, 2009.
DOI : 10.1159/000258497

A. Lievre, E. Rouleau, B. Buecher, and E. Mitry, Clinical significance of BRAF mutations in colorectal cancer]. Bull Cancer, pp.1441-52, 2010.

N. Normanno, S. Tejpar, and F. Ciardiello, Re: Biomarkers Predicting Clinical Outcome of Epidermal Growth Factor Receptor-Targeted Therapy in Metastatic Colorectal Cancer, JNCI Journal of the National Cancer Institute, vol.7, issue.11, pp.573-578, 2010.
DOI : 10.1056/NEJMra0707704

S. Siena, A. Sartore-bianchi, D. Nicolantonio, F. Balfour, J. Bardelli et al., Response: Re: Biomarkers Predicting Clinical Outcome of Epidermal Growth Factor Receptor-Targeted Therapy in Metastatic Colorectal Cancer, JNCI Journal of the National Cancer Institute, vol.4, issue.10, pp.573-578, 2010.
DOI : 10.1371/journal.pone.0007287

J. Souglakos, J. Philips, R. Wang, S. Marwah, M. Silver et al., Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer, British Journal of Cancer, vol.62, issue.3, pp.465-72, 2009.
DOI : 10.1126/science.1145720

A. Bardelli and S. Siena, Molecular Mechanisms of Resistance to Cetuximab and Panitumumab in Colorectal Cancer, Journal of Clinical Oncology, vol.28, issue.7, pp.1254-61, 2010.
DOI : 10.1200/JCO.2009.24.6116

S. Kim, J. Kim, J. Kim, C. Yun, E. Kim et al., Acquired resistance to cetuximab is mediated by increased PTEN instability and leads cross-resistance to gefitinib in HCC827 NSCLC cells, Cancer Letters, vol.296, issue.2, pp.150-159, 2010.
DOI : 10.1016/j.canlet.2010.04.006

A. Sartore-bianchi, M. Martini, F. Molinari, S. Veronese, M. Nichelatti et al., PIK3CA Mutations in Colorectal Cancer Are Associated with Clinical Resistance to EGFR-Targeted Monoclonal Antibodies, Cancer Research, vol.69, issue.5, pp.1851-1858, 2009.
DOI : 10.1158/0008-5472.CAN-08-2466

W. Shen, A. Balajee, J. Wang, H. Wu, C. Eng et al., Essential role for nuclear PTEN in maintaining chromosomal integrity. Cell, pp.157-70, 2007.

P. Cairns, K. Okami, S. Halachmi, N. Halachmi, M. Esteller et al., Frequent inactivation of PTEN/MMAC1 in primary prostate cancer. Cancer Res, pp.4997-5000, 1997.

H. Feilotter, M. Nagai, A. Boag, C. Eng, and L. Mulligan, Analysis of PTEN and the 10q23 region in primary prostate carcinomas. Oncogene, pp.1743-1751, 1998.

Y. Whang, X. Wu, H. Suzuki, R. Reiter, C. Tran et al., Inactivation of the tumor suppressor PTEN/MMAC1 in advanced human prostate cancer through loss of expression, Proceedings of the National Academy of Sciences, vol.94, issue.17, pp.5246-50, 1998.
DOI : 10.1073/pnas.94.17.9052

P. Guldberg, P. Thor-straten, A. Birck, V. Ahrenkiel, A. Kirkin et al., Disruption of the MMAC1/PTEN gene by deletion or mutation is a frequent event in malignant melanoma, Cancer Res, vol.57, issue.17, pp.3660-3663, 1997.

K. Gronbaek, J. Zeuthen, P. Guldberg, E. Ralfkiaer, and K. Hou-jensen, Alterations of the MMAC1/PTEN gene in lymphoid malignancies, Blood, vol.91, issue.11, pp.4388-90, 1998.

A. Perren, L. Weng, A. Boag, U. Ziebold, K. Thakore et al., Immunohistochemical Evidence of Loss of PTEN Expression in Primary Ductal Adenocarcinomas of the Breast, The American Journal of Pathology, vol.155, issue.4, pp.1253-60, 1999.
DOI : 10.1016/S0002-9440(10)65227-3

N. Nassif, G. Lobo, X. Wu, C. Henderson, C. Morrison et al., PTEN mutations are common in sporadic microsatellite stable colorectal cancer, Oncogene, vol.23, issue.2, 2004.
DOI : 10.1038/sj.onc.1207059

Y. Nagata, K. Lan, X. Zhou, M. Tan, F. Esteva et al., PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell, pp.117-144, 2004.

B. Dave, I. Migliaccio, M. Gutierrez, M. Wu, G. Chamness et al., Loss of Phosphatase and Tensin Homolog or Phosphoinositol-3 Kinase Activation and Response to Trastuzumab or Lapatinib in Human Epidermal Growth Factor Receptor 2???Overexpressing Locally Advanced Breast Cancers, Journal of Clinical Oncology, vol.29, issue.2, pp.166-73
DOI : 10.1200/JCO.2009.27.7814

D. Wheeler, S. Huang, T. Kruser, M. Nechrebecki, E. Armstrong et al., Mechanisms of acquired resistance to cetuximab: role of HER (ErbB) family members, Oncogene, vol.10, issue.28, pp.3944-56, 2008.
DOI : 10.4161/cbt.5.10.3226

F. Cappuzzo, M. Varella-garcia, G. Finocchiaro, M. Skokan, S. Gajapathy et al., Primary resistance to cetuximab therapy in EGFR FISH-positive colorectal cancer patients, British Journal of Cancer, vol.57, issue.1, pp.83-92, 2008.
DOI : 10.1002/cncr.10945

T. Winder, W. Zhang, D. Yang, Y. Ning, P. Bohanes et al., Germline polymorphisms in genes involved in the IGF1 pathway predict efficacy of cetuximab in wildtype KRAS mCRC patients. Clin Cancer Res, pp.5591-602, 2010.

A. Oden-gangloff, D. Fiore, F. Bibeau, F. Lamy, A. Bougeard et al., TP53 mutations predict disease control in metastatic colorectal cancer treated with cetuximab-based chemotherapy, British Journal of Cancer, vol.97, issue.8, pp.1330-1335, 2009.
DOI : 10.1200/JCO.2005.04.096

B. Jacobs, D. Roock, W. Piessevaux, H. , V. Oirbeek et al., Amphiregulin and Epiregulin mRNA Expression in Primary Tumors Predicts Outcome in Metastatic Colorectal Cancer Treated With Cetuximab, Journal of Clinical Oncology, vol.27, issue.30, pp.5068-74, 2009.
DOI : 10.1200/JCO.2008.21.3744

S. Siena, A. Sartore-bianchi, D. Nicolantonio, F. Balfour, J. Bardelli et al., Biomarkers Predicting Clinical Outcome of Epidermal Growth Factor Receptor???Targeted Therapy in Metastatic Colorectal Cancer, JNCI: Journal of the National Cancer Institute, vol.27, issue.28, pp.1308-1332, 2009.
DOI : 10.1038/onc.2008.19

A. Lopez-albaitero and R. Ferris, Immune Activation by Epidermal Growth Factor Receptor???Specific Monoclonal Antibody Therapy for Head and Neck Cancer, Archives of Otolaryngology???Head & Neck Surgery, vol.133, issue.12, pp.1277-81, 2007.
DOI : 10.1001/archotol.133.12.1277

D. Paez, L. Pare, I. Espinosa, J. Salazar, E. Del-rio et al., Immunoglobulin G fragment C receptor polymorphisms and KRAS mutations: Are they useful biomarkers of clinical outcome in advanced colorectal cancer treated with anti-EGFR-based therapy?, Cancer Science, vol.24, issue.9, pp.2048-53, 2010.
DOI : 10.1111/j.1349-7006.2010.01621.x

F. Ciardiello, R. Bianco, R. Caputo, R. Caputo, V. Damiano et al., Antitumor Activity of ZD6474, a Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor, in Human Cancer Cells with Acquired Resistance to Antiepidermal Growth Factor Receptor Therapy, Clinical Cancer Research, vol.10, issue.2, pp.784-93, 2004.
DOI : 10.1158/1078-0432.CCR-1100-03

D. Vallbohmer, W. Zhang, M. Gordon, D. Yang, Y. J. Press et al., Molecular Determinants of Cetuximab Efficacy, Journal of Clinical Oncology, vol.23, issue.15, pp.3536-3580, 2005.
DOI : 10.1200/JCO.2005.09.100

S. Tejpar, M. Peeters, Y. Humblet, H. Gelderblom, J. Vermorken et al., Phase I/II study of cetuximab dose-escalation in patients with metastatic colorectal cancer with no or slight skin reactions on cetuximab standard dose treatment (Everest) : pharmacokinetic, pharmacodynamic and efficacy data, Proc Am Soc Clin Oncol, vol.25, p.4037, 2007.

R. Sipples, Common Side Effects of Anti-EGFR Therapy: Acneform Rash, Seminars in Oncology Nursing, vol.22, issue.1, pp.28-34, 2006.
DOI : 10.1016/j.soncn.2006.01.013

J. Ludwig and J. Weinstein, Biomarkers in Cancer Staging, Prognosis and Treatment Selection, Nature Reviews Cancer, vol.2, issue.Suppl. 8, pp.845-56, 2005.
DOI : 10.1016/S1471-4892(02)00185-6

S. Mandrekar and D. Sargent, Clinical Trial Designs for Predictive Biomarker Validation: Theoretical Considerations and Practical Challenges, Journal of Clinical Oncology, vol.27, issue.24, pp.4027-4061, 2009.
DOI : 10.1200/JCO.2009.22.3701

B. Freidlin and R. Simon, Adaptive Signature Design: An Adaptive Clinical Trial Design for Generating and Prospectively Testing A Gene Expression Signature for Sensitive Patients, Clinical Cancer Research, vol.11, issue.21, pp.7872-7880, 2005.
DOI : 10.1158/1078-0432.CCR-05-0605

G. Marko-varga, A. Ogiwara, T. Nishimura, T. Kawamura, K. Fujii et al., Personalized Medicine and Proteomics:?? Lessons from Non-Small Cell Lung Cancer, Journal of Proteome Research, vol.6, issue.8, pp.2925-2960, 2007.
DOI : 10.1021/pr070046s

T. Okano, T. Kondo, K. Fujii, T. Nishimura, T. Takano et al., Proteomic Signature Corresponding to the Response to Gefitinib (Iressa, ZD1839), an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in Lung Adenocarcinoma, Clinical Cancer Research, vol.13, issue.3, pp.799-805, 2007.
DOI : 10.1158/1078-0432.CCR-06-1654

G. Perkins, A. Lievre, C. Ramacci, T. Meatchi, A. De-reynies et al., Additional value of EGFR downstream signaling phosphoprotein expression to KRAS status for response to anti-EGFR antibodies in colorectal cancer, International Journal of Cancer, vol.67, issue.6, pp.1321-1352, 2010.
DOI : 10.1002/ijc.25152

C. Duby and R. S. , Analyse en composantes principales, 2006.

B. Falissard, Comprendre et utiliser les statistiques dans les sciences de la vie: Masson, 2005.

J. Jolliffe, Principal component analysis, 2002.

P. Cassin, Analyse des données et des panels de données: De Boeck Université, 1999.

F. Chergui, A. Chretien, S. Bouali, C. Ramacci, M. Rouyer et al., Validation of a Phosphoprotein Array Assay for Characterization of Human Tyrosine Kinase Receptor Downstream Signaling in Breast Cancer, Clinical Chemistry, vol.55, issue.7, pp.1327-1363, 2009.
DOI : 10.1373/clinchem.2008.116632

J. Pan, H. Chen, Y. Sun, J. Zhang, and X. Luo, Comparative Proteomic Analysis of Non-small-cell Lung Cancer and Normal Controls Using Serum Label-Free Quantitative Shotgun Technology, Lung, vol.120, issue.10, pp.255-61, 2008.
DOI : 10.1002/ijc.22041

Z. Boyd, Q. Wu, O. Brien, C. Spoerke, J. Savage et al., Proteomic analysis of breast cancer molecular subtypes and biomarkers of response to targeted kinase inhibitors using reverse-phase protein microarrays, Molecular Cancer Therapeutics, vol.7, issue.12, pp.3695-706, 2008.
DOI : 10.1158/1535-7163.MCT-08-0810

K. Verhoeckx, S. Bijlsma, E. De-groene, R. Witkamp, J. Van-der-greef et al., A combination of proteomics, principal component analysis and transcriptomics is a powerful tool for the identification of biomarkers for macrophage maturation in the U937 cell line, PROTEOMICS, vol.4, issue.4, pp.1014-1042, 2004.
DOI : 10.1002/pmic.200300669

J. Pagès, Analyse factorielle multiple appliquée aux variables qualitatives et aux données mixtes. Revue de Statistique Appliquée, pp.5-37, 2002.

A. Miyanaga, A. Gemma, R. Noro, K. Kataoka, K. Matsuda et al., Antitumor activity of histone deacetylase inhibitors in non-small cell lung cancer cells: development of a molecular predictive model, Molecular Cancer Therapeutics, vol.7, issue.7, pp.1923-1953, 2008.
DOI : 10.1158/1535-7163.MCT-07-2140

I. Pinhel, F. Macneill, M. Hills, J. Salter, S. Detre et al., Extreme loss of immunoreactive p-Akt and p-Erk1/2 during routine fixation of primary breast cancer, Breast Cancer Research, vol.28, issue.Suppl, p.76, 2010.
DOI : 10.1200/JCO.2009.26.1602

S. Siddiqui and D. Rimm, Pre-analytic variables and phospho-specific antibodies: the Achilles heel of immunohistochemistry, Breast Cancer Research, vol.22, issue.6, p.113, 2010.
DOI : 10.1038/modpathol.2009.117

V. Espina, C. Mueller, K. Edmiston, M. Sciro, E. Petricoin et al., Tissue is alive: New technologies are needed to address the problems of protein biomarker pre-analytical variability, PROTEOMICS - CLINICAL APPLICATIONS, vol.121, issue.8, pp.874-82, 2009.
DOI : 10.1016/S0002-9440(10)64472-0

D. Rimm and I. Beyond, Accurate, Reproducible, and Quantitative Measurement of Protein Analyte Concentrations in Fixed Tissue. College of American Pathologists Foundation's Futurescape conference, 2009.

N. West, M. Dattani, P. Mcshane, G. Hutchins, J. Grabsch et al., The proportion of tumour cells is an independent predictor for survival in colorectal cancer patients, British Journal of Cancer, vol.26, issue.10, pp.1519-1542, 2010.
DOI : 10.1016/j.humpath.2007.04.008

M. Ratain and R. Glassman, Biomarkers in phase I oncology trials: signal, noise, or expensive distraction? Clin Cancer Res, Nov, vol.151322, issue.1, pp.6545-6553, 2007.

V. Belief, F. Boissiere, F. Bibeau, C. Desmetz, M. Berthe et al., Proteomic analysis of RCL2 paraffin-embedded tissues, J Cell Mol Med, vol.12, issue.5B, pp.2027-2063, 2008.

C. Delfour, P. Roger, C. Bret, M. Berthe, P. Rochaix et al., RCL2, a New Fixative, Preserves Morphology and Nucleic Acid Integrity in Paraffin-Embedded Breast Carcinoma and Microdissected Breast Tumor Cells, The Journal of Molecular Diagnostics, vol.8, issue.2, pp.157-69, 2006.
DOI : 10.2353/jmoldx.2006.050105

D. Gruson and S. Bodovitz, Rapid emergence of multimarker strategies in laboratory medicine, Biomarkers, vol.55, issue.6, pp.289-96, 2010.
DOI : 10.1002/hep.20506

G. Ruiz, M. Floor, K. Steinberg, S. Grunberg, K. Thunnissen et al., Combined assessment of EGFR pathway-related molecular markers and prognosis of NSCLC patients, British Journal of Cancer, vol.9, issue.1, pp.145-52, 2009.
DOI : 10.1158/1078-0432.CCR-05-1492

A. Sartore-bianchi, D. Nicolantonio, F. Nichelatti, M. Molinari, F. et al., Multi-Determinants Analysis of Molecular Alterations for Predicting Clinical Benefit to EGFR-Targeted Monoclonal Antibodies in Colorectal Cancer, PLoS ONE, vol.92, issue.10, p.7287, 2009.
DOI : 10.1371/journal.pone.0007287.t005

D. Petris and P. , Discovery and validation of protein biomarkers for lung cancer, Thèse, 2010.

I. Mellinghoff, M. Wang, I. Vivanco, D. Haas-kogan, S. Zhu et al., Molecular Determinants of the Response of Glioblastomas to EGFR Kinase Inhibitors, New England Journal of Medicine, vol.353, issue.19, pp.2012-2036, 2005.
DOI : 10.1056/NEJMoa051918

L. Bonetta, Interactome under construction, Nature, vol.464, issue.7325, 2010.
DOI : 10.1038/468851a

URL : http://www.nature.com/nature/journal/v468/n7325/pdf/468851a.pdf

B. Kholodenko, Employing Systems Biology to Quantify Receptor Tyrosine Kinase Signaling in Time and Space Springer, 2010.

B. Kholodenko, J. Hancock, and W. Kolch, Signalling ballet in space and time, Nature Reviews Molecular Cell Biology, vol.3, issue.6, pp.414-440
DOI : 10.1038/msb.2009.19

R. Simon, Clinical trial designs for evaluating the medical utility of prognostic and predictive biomarkers in oncology, Personalized Medicine, vol.6, issue.1, pp.33-47, 2010.
DOI : 10.1002/sim.2825

A. Vickers, K. Jang, D. Sargent, H. Lilja, and M. Kattan, Systematic review of statistical methods used in molecular marker studies in cancer, Cancer, vol.26, issue.8, pp.1862-1870, 2008.
DOI : 10.1155/2004/202031